As per the report published by Allied Market Research, the global pulmonary arterial hypertension market generated $7.2 billion in 2021, and is expected to reach $12 billion by 2031, growing at a CAGR of 5.2% from 2022 to 2031. The report provides an in-depth analysis of top segments, changing market trends, value chains, key investment pockets, competitive scenarios, and regional landscape. The report is an essential and helpful source of information for leading market players, investors, new entrants, and stakeholders in formulating new strategies for the future and taking steps to strengthen their position in the market.
Download Free Sample Report- https://www.alliedmarketresearch.com/request-sample/5470
The report segments the global pulmonary arterial hypertension market on the basis of drug type, type, route of administration, and region.
Based on drug type, the prostacyclin and prostacyclin analogs segment held the largest share in 2021, accounting for more than half of the market. In addition, the segment is estimated to register the highest CAGR of 5.5% during the forecast period.
On the basis of type, the branded segment dominated the market in terms of revenue in 2021, accounting for more than four-fifths of the market. However, the generics segment is estimated to register the highest CAGR of 5.7% from 2022 to 2031.
Based on route of administration, the oral segment held the largest share in 2021, accounting for nearly two-thirds of the market. In addition, the segment is projected to manifest the highest CAGR of 5.6% during the forecast period.
For Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/5470
The global pulmonary arterial hypertension market is analyzed across several regions such as North America, LAMEA, Asia-Pacific, and Europe. The market across North America held the lion’s share in 2021, accounting for more than two-fifths of the market. However, the market across Asia-Pacific is expected to register the highest CAGR of 7.2% from 2022 to 2031.
The global pulmonary arterial hypertension market report includes an in-depth analysis of the prime market players such as Bayer AG, GlaxoSmithKline Plc, Gilead Sciences, Inc., Johnson & Johnson, Lupin Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation and Viatris Inc.
The report analyzes these key players in the global pulmonary arterial hypertension market. These players have adopted various strategies such as new product launches, expansion, partnerships, and others to increase their market penetration and strengthen their position in the industry. The report is helpful in determining the business performance, operating segments, product portfolio, and developments of every market player.
The global pulmonary arterial hypertension (PAH) market size was valued at USD 5.0 billion in 2015 and is anticipated to reach USD 8.7 billion by 2025.
PAH occurs when the pulmonary arteries thicken or grow rigid.
These drugs have superiority over existing therapy options with respect to the therapeutic efficacy, route of administration, and side-effects.Download Free Sample Report @ https://www.millioninsights.com/industry-reports/pulmonary-arterial-hypertension-pah-market/request-sampleA new drug called Uptravi (selexipag), which is a selective IP prostacyclin receptor agonist, is expected to be launched in 2016 and is likely to drive growth of the prostacyclin and prostacyclin analogs market.
In the U.S., the Orphan Drug Act (ODA) encourages pharmaceutical industries to develop orphan drugs by offering benefits such as tax credits, research grants, and orphan drug exclusivity of seven years.
Transplantation- Lung or heart-lung transplant might be an option especially for younger people who have idiopathic pulmonary arterial hypertension.Geographically, PAH market is segmented into North America, Europe, Asia Pacific, Latin America, MEA, and Rest of the World.
North America held the maximum share of market for PAH in terms of revenue in 2013, which is then followed by Europe.
The ‘Pulmonary Arterial Hypertension (PAH)- Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PAH in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
Also the Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Pulmonary Arterial Hypertension (PAH) from 2016 to 2027 segmented by seven major markets.Complete report on Global Pulmonary Arterial Hypertension (PAH) Market Size, Trends And Forecast Report 2014 – 2025 Enquire more@ https://franknraf.com/reports/global-pulmonary-arterial-hypertension-pah-market-size-trends-and-forecast-report-2014-2025/The Report research analysis also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered The United States EU5 (Germany, France, Italy, Spain and the United Kingdom) Japan Study Period: 2016-2027 Pulmonary Arterial Hypertension (PAH) - Disease Understanding and Treatment Algorithm.Get Sample copy of the report@ https://franknraf.com/sample-report/?rpt_id=6169The Pulmonary Arterial Hypertension (PAH) market report gives the thorough understanding of the Pulmonary Arterial Hypertension (PAH) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends.
The research analysis also provides treatment algorithms and treatment guidelines for Pulmonary Arterial Hypertension (PAH) in the US, Europe, and Japan.
Pulmonary Arterial Hypertension (PAH) Epidemiology The Pulmonary Arterial Hypertension (PAH) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries.
Also it helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.Pulmonary Arterial Hypertension (PAH) Drug Chapters This segment of the Pulmonary Arterial Hypertension (PAH) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
